Are Orchid Pharma latest results good or bad?

Orchid Pharma has reported its financial results for the quarter ending June 2025, which indicate a notable decline across several key metrics. The company's net sales for the quarter were recorded at Rs 172.93 crore, which represents a significant reduction compared to the average net sales of the previous four quarters. This decline in sales is accompanied by a dramatic fall in Profit Before Tax (PBT), which decreased to Rs 2.26 crore, reflecting a substantial drop from the average PBT in prior quarters. Similarly, Profit After Tax (PAT) also saw a decline, reaching Rs 14.91 crore, which is lower than the average PAT from previous periods.
The operating profit margin has contracted to 8.19%, marking the lowest level in five quarters, suggesting a decrease in operational efficiency. Furthermore, a large portion of the PBT, specifically 83.52%, was derived from non-operating income, raising questions about the sustainability of the company's core business operations. Earnings per share (EPS) fell to Rs 2.94, indicating a decline in profitability for shareholders.

In light of these results, Orchid Pharma experienced an adjustment in its evaluation, reflecting the challenges faced during this reporting period. The data illustrates a clear trend of declining performance across multiple financial metrics for the company.